- Home
- Publications
- Publication Search
- Publication Details
Title
Translational development of splice-modifying antisense oligomers
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 17, Issue 1, Pages 15-30
Publisher
Informa UK Limited
Online
2016-11-02
DOI
10.1080/14712598.2017.1250880
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
- (2016) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Contributions of Japanese patients to development of antisense therapy for DMD
- (2016) Masafumi Matsuo et al. BRAIN & DEVELOPMENT
- Pharmacokinetics, pharmacodynamics, and efficacy of a small-moleculeSMN2splicing modifier in mouse models of spinal muscular atrophy
- (2016) Xin Zhao et al. HUMAN MOLECULAR GENETICS
- Antisense molecules: A new class of drugs
- (2016) Daniel P. Potaczek et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
- (2016) Volker Straub et al. LANCET NEUROLOGY
- The case for eteplirsen: Paving the way for precision medicine
- (2016) M. Carrie Miceli et al. MOLECULAR GENETICS AND METABOLISM
- DMDgenotypes and loss of ambulation in the CINRG Duchenne Natural History Study
- (2016) Luca Bello et al. NEUROLOGY
- Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
- (2016) Eugenio Mercuri et al. NEUROMUSCULAR DISORDERS
- Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy
- (2016) Eugenio Mercuri et al. PLoS One
- Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
- (2016) Suzan M. Hammond et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice
- (2016) Gang Han et al. Nature Communications
- Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies
- (2016) Luca Bello et al. Scientific Reports
- Fructose Promotes Uptake and Activity of Oligonucleotides With Different Chemistries in a Context-dependent Manner in mdx Mice
- (2016) Limin Cao et al. Molecular Therapy-Nucleic Acids
- Mechanisms and Regulation of Alternative Pre-mRNA Splicing
- (2015) Yeon Lee et al. Annual Review of Biochemistry
- Improving clinical trial design for Duchenne muscular dystrophy
- (2015) Luciano Merlini et al. BMC Neurology
- Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
- (2015) Ashley Guncay et al. Future Medicinal Chemistry
- Oligonucleotide therapeutics: chemistry, delivery and clinical progress
- (2015) Vivek K Sharma et al. Future Medicinal Chemistry
- The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
- (2015) Catherine L. Bladen et al. HUMAN MUTATION
- The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
- (2015) Valeria Ricotti et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman Primates
- (2015) Kathrin Meyer et al. MOLECULAR THERAPY
- SMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice
- (2015) James Palacino et al. Nature Chemical Biology
- Exon 53 skipping of the dystrophin gene in patients with Duchenne muscular dystrophy by systemic administration of NS-065/NCNP-01: A phase 1, dose escalation, first-in-human study
- (2015) H. Komaki et al. NEUROMUSCULAR DISORDERS
- Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy
- (2015) Stephen Lynn et al. NEUROMUSCULAR DISORDERS
- 2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF
- (2015) Wen Shen et al. NUCLEIC ACIDS RESEARCH
- Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse
- (2015) Vicki L. McGovern et al. PLoS One
- The emperor's new dystrophin: finding sense in the noise
- (2015) S.D. Wilton et al. TRENDS IN MOLECULAR MEDICINE
- Antisense oligonucleotide development for the treatment of muscular dystrophies
- (2015) Tri Le Bao et al. Expert Opinion on Orphan Drugs
- Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
- (2015) Silvana M G Jirka et al. Molecular Therapy-Nucleic Acids
- Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient
- (2015) Kane Greer et al. Molecular Genetics & Genomic Medicine
- New developments in exon skipping and splice modulation therapies for neuromuscular diseases
- (2014) Aleksander Touznik et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models
- (2014) Erkan Y. Osman et al. HUMAN MOLECULAR GENETICS
- Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
- (2014) Thomas Voit et al. LANCET NEUROLOGY
- Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice
- (2014) Nicolas Wein et al. NATURE MEDICINE
- Biomarkers and surrogate endpoints in Duchenne: Meeting report
- (2014) Annemieke Aartsma-Rus et al. NEUROMUSCULAR DISORDERS
- Dystrophin as a therapeutic biomarker: Are we ignoring data from the past?
- (2014) Steve D. Wilton et al. NEUROMUSCULAR DISORDERS
- Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes
- (2014) Marika Pane et al. PLoS One
- SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
- (2014) N. A. Naryshkin et al. SCIENCE
- Exon-Skipping Therapy: A Roadblock, Detour, or Bump in the Road?
- (2014) E. P. Hoffman et al. Science Translational Medicine
- Exon identity crisis: disease-causing mutations that disrupt the splicing code
- (2014) Timothy Sterne-Weiler et al. GENOME BIOLOGY
- What Can We Learn From Clinical Trials of Exon Skipping for DMD?
- (2014) Qi-long Lu et al. Molecular Therapy-Nucleic Acids
- Eteplirsen for the treatment of Duchenne muscular dystrophy
- (2013) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Spinal muscular atrophy: An update on therapeutic progress
- (2013) Joonbae Seo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Strategies for Postmarketing Surveillance of Drugs for Rare Diseases
- (2013) A S Kesselheim et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches
- (2013) Brunhilde Wirth et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy
- (2013) Anna G Mayhew et al. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
- Pluronic–PEI copolymers enhance exon-skipping of 2′-O-methyl phosphorothioate oligonucleotide in cell culture and dystrophic mdx mice
- (2013) M Wang et al. GENE THERAPY
- A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice
- (2013) Haiyan Zhou et al. HUMAN GENE THERAPY
- Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy
- (2013) J. C. van den Bergen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy
- (2013) Natalia N. Singh et al. NUCLEIC ACIDS RESEARCH
- Species-specific Inflammatory Responses as a Primary Component for the Development of Glomerular Lesions in Mice and Monkeys Following Chronic Administration of a Second-generation Antisense Oligonucleotide
- (2013) Kendall S. Frazier et al. TOXICOLOGIC PATHOLOGY
- Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
- (2013) HaiFang Yin et al. Molecular Therapy-Nucleic Acids
- LTBP4genotype predicts age of ambulatory loss in duchenne muscular dystrophy
- (2012) Kevin M. Flanigan et al. ANNALS OF NEUROLOGY
- Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
- (2012) Thomas O. Crawford et al. PLoS One
- Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy
- (2012) G. C. Kendall et al. Science Translational Medicine
- Innovative study design for paediatric clinical trials
- (2011) Paola Baiardi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
- (2011) Paul N. Porensky et al. HUMAN MOLECULAR GENETICS
- A framework for applying unfamiliar trial designs in studies of rare diseases
- (2011) Samir Gupta et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
- (2011) Yimin Hua et al. NATURE
- Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
- (2011) Nathalie M. Goemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression
- (2011) Céline Vanderplanck et al. PLoS One
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
- (2011) M. A. Passini et al. Science Translational Medicine
- RNA-targeted splice-correction therapy for neuromuscular disease
- (2010) M. J. A. Wood et al. BRAIN
- Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene
- (2010) Kevin M. Flanigan et al. HUMAN MUTATION
- Dystrophin Isoform Induction In Vivo by Antisense-mediated Alternative Splicing
- (2010) Sue Fletcher et al. MOLECULAR THERAPY
- A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
- (2010) Ans T. van der Ploeg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a novel muscle targeting peptide in mdx mice
- (2010) Yiqi Seow et al. PEPTIDES
- Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy
- (2010) Annemieke Aartsma-Rus RNA Biology
- Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs
- (2009) Toshifumi Yokota et al. ANNALS OF NEUROLOGY
- Development of Antisense-Mediated Exon Skipping as a Treatment for Duchenne Muscular Dystrophy
- (2009) Hans Heemskerk et al. Annals of the New York Academy of Sciences
- Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers
- (2009) Patrick Iversen et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino
- (2009) B Wu et al. GENE THERAPY
- In vivocomparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping
- (2009) Hans A. Heemskerk et al. JOURNAL OF GENE MEDICINE
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
- (2009) Maria Kinali et al. LANCET NEUROLOGY
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
- (2009) Katharine Bushby et al. LANCET NEUROLOGY
- Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping
- (2009) Chalermchai Mitrpant et al. MOLECULAR THERAPY
- Cationic PMMA Nanoparticles Bind and Deliver Antisense Oligoribonucleotides Allowing Restoration of Dystrophin Expression in the mdx Mouse
- (2009) Paola Rimessi et al. MOLECULAR THERAPY
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Spinal muscular atrophy
- (2008) Mitchell R Lunn et al. LANCET
- Regulation of SMN Protein Stability
- (2008) B. G. Burnett et al. MOLECULAR AND CELLULAR BIOLOGY
- Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle
- (2008) Gabriela D. Ivanova et al. NUCLEIC ACIDS RESEARCH
- Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy
- (2008) G. E. Oprea et al. SCIENCE
- DMDpseudoexon mutations: splicing efficiency, phenotype, and potential therapy
- (2007) Olga L. Gurvich et al. ANNALS OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now